Safety and efficacy of a humanized<scp>CD19</scp>chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Safety and efficacy of a humanizedCD19chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia

Published:2022-02-25 Issue:6 Volume:97 Page:711-718
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Shi Ming¹,Li Li²,Wang Shiyuan³,Cheng Hai³,Chen Wei³,Sang Wei³,Qi Kunming³,Li Zhenyu³,Wang Gang¹,Li Huizhong¹,Lan Jianping⁴,Huang Jinqi⁵,Fei Xiaoming⁶,Yu Min⁷,Li Fei⁷,Qiao Jianlin⁸,Wu Qingyun⁸,Zeng Lingyu⁸,Jing Guangjun⁹,Zheng Junnian¹,Gale Robert Peter¹⁰^ORCID,Xu Kailin³⁸^ORCID,Cao Jiang³^ORCID

Affiliation:

1. Jiangsu Center for the Collaboration and Innovation of Cancer Biotheraty, Cancer Institute Xuzhou Medical University Xuzhou China

2. Department of Gastroenterology The Affiliated Hospital of Xuzhou Medical University Xuzhou China

3. Department of Hematology The Affiliated Hospital of Xuzhou Medical University Xuzhou China

4. Department of Hematology Zhejiang Provincial People's Hospital Zhejiang China

5. Department of Hematology The Affiliated Hospital of Guangdong Medical University Zhanjiang China

6. Department of Hematology The Affiliated Hospital of Jiangsu University Zhenjiang China

7. Center of Hematology The First Affiliated Hospital of Nanchang University Nanchang China

8. Jiangsu Bone Marrow Stem Cell Institute, Xuzhou Medical University Xuzhou China

9. iCARTAB Biomedical Co. Ltd Suzhou China

10. Centre for Hematology Research, Department of Immunology and Inflammation Imperial College London London UK

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26506

Reference34 articles.

1. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

2. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

3. Fully human CD19-specific chimeric antigen receptors for T-cell therapy

4. Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

5. Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial;Nature Communications;2024-04-20

2. Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia;Cancer;2024-04-05

3. Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia;Transfusion Medicine and Hemotherapy;2023-08-22

4. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects;Signal Transduction and Targeted Therapy;2023-08-18

5. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer;Journal of Translational Medicine;2023-04-12